WALD
Waldencast plc
NASDAQ · Technology · Software - Application · US
$0.88
+0.00%Oct 15, 2026, 20:15 UTC
Waldencast plc filed a Form 15 with the SEC to terminate registration of its Class A ordinary shares and warrants and suspend its Exchange Act reporting obligations.
Source:Sep 28, 2026, 20:35 UTC
Waldencast plc reported its operating results for the six months ended June 30, 2026.
Source:Sep 14, 2026, 10:55 UTC
Waldencast plc's board approved the voluntary delisting of its Class A Ordinary Shares and Warrants from Nasdaq and deregistration under the Exchange Act, with a Form 25 expected to be filed with the SEC on or about September 24, 2026.
Jul 30, 2026, 20:30 UTC
Waldencast completed the sale of its Obagi Medical business to Bridgepoint for up to $460 million.
Source:Jul 27, 2026, 17:59 UTC
Waldencast Plc filed a lawsuit in Delaware's Chancery Court against former Obagi CEO Jaime Castle and former parent Cedarwalk Skincare Ltd., alleging a channel-stuffing scheme that inflated Obagi's earnings by $50 million and caused Waldencast to overpay by hundreds of millions of dollars.
Source:Jun 15, 2026, 13:00 UTC
The FDA approved Obagi saypha ChIQ injectable hyaluronic acid gel for Obagi Medical, a brand of Waldencast plc.
Source:Jun 1, 2026, 10:59 UTC
Waldencast plc agreed to sell its Obagi Medical business to Bridgepoint for up to $460 million.
Source: